Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 34, 2020 - Issue 18
444
Views
12
CrossRef citations to date
0
Altmetric
Research Articles

Isolation, characterization, and xanthine oxidase inhibitory activities of flavonoids from the leaves of Perilla frutescens

, , , ORCID Icon, , , , & show all
Pages 2566-2572 | Received 28 Sep 2018, Accepted 01 Nov 2018, Published online: 02 Jan 2019

References

  • Abeles AM. 2012. Febuxostat hypersensitivity. J Rheumatol. 39(3):659.
  • Borghi C, Desideri G. 2016. Urate-lowering drugs and prevention of cardiovascular disease: the emerging role of xanthine oxidase inhibition. Hypertension. 67(3):496–498.
  • Clark-Lewis JW. 1968. Flavan derivatives. XXI. nuclear magnetic resonance spectra, configuration, and conformation of flavan derivatives. Aust J Chem. 21:2059–2075.
  • Consonni R, Cagliani LR, Docimo T, Romane A, Ferrazzi P. 2013. Perilla frutescens (L.) Britton: honeybee forage and preliminary results on the metabolic profiling by NMR spectroscopy. Nat Prod Res. 19:1743–1748.
  • Ferrazzi P, Vercelli M, Chakir A, Romane A, Mattana M, Consonni R. 2017. Pollination effects on antioxidant content of Perilla frutescens seeds analysed by NMR spectroscopy. Nat Prod Res. 23:2705–2711.
  • Huang HQ, Li HL, Tang J, Lv YF, Zhang WD. 2008. A new aurone and other phenolic constituents from Veratrum schindleri Loes. f. Biochem Syst Ecol. 36(7):590–592.
  • Huo LN, Wang W, Liu Y, Liu XH, Zhang L, Cheng K, Liu K, Gao H. 2016. Chemical constituents from Perilla frutescens. Chin Tradit Herb Drugs. 47:26–31.
  • Huo LN, Wang W, Zhang CY, Shi HB, Liu Y, Liu XH, Guo BH, Zhao DM, Gao H. 2015. Bioassay-guided isolation and identification of xanthine oxidase inhibitory constituents from the leaves of Perilla frutescens. Molecules. 20(10):17848–17859.
  • Li M, Hu XL, Fan YL, Li K, Zhang XW, Hou WS, Tang ZY. 2016. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep. 6:19520.
  • Lin M-S, Dai Y-S, Pwu R-F, Chen Y-H, Chang N-C. 2005. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J. 35(3):188–190.
  • Liu K, Wang W, Guo BH, Gao H, Liu Y, Liu XH, Yao HL, Cheng K. 2016. Chemical evidence for potent xanthine oxidase inhibitory activity of ethyl acetate extract of Citrus aurantium L. Dried immature fruits. Molecules. 21(3):302.
  • Liu Y, Liu XH, Zhou S, Gao H, Li GL, Guo WJ, Fang XY, Wang W. 2017. Perillanolides A and B, new monoterpene glycosides from the leaves of Perilla frutescens. Rev Bras Farmacogn. 27(5):564–568.
  • Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bavinck JNB, Sidoroff A, Schneck J, Roujeau J, Flahault A. 2008. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 128(1):35–44.
  • Seabra RM, Andrade PB, Ferreres F, Moreira MM. 1997. Methoxylated aurones from Cyperus capitatus. Phytochemistry. 45(4):839–840.
  • Slade D, Ferreira D, Marais JPJ. 2005. Circular dichroism, a powerful tool for the assessment of absolute configuration of flavonoids. Phytochemistry. 66(18):2177–2215.
  • Šmelcerović A, Tomović K, Šmelcerović Ž, Petronijević Ž, Kocić G, Tomašič T, Jakopin Ž, Anderluh M. 2017. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity. Eur J Med Chem. 135:491–516.
  • Yaylacı S, Demir MV, Temiz T, Tamer A, Uslan MI. 2012. Allopurinol-induced DRESS syndrome. Indian J Pharmacol. 44(3):412–414.
  • Yuan HP, Yu CL, Li XH, Sun L, Zhu XQ, Zhao CX, Zhang Z, Yang Z. 2015. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies. J Clin Endocrinol Metab. 100(11):4198–4207.
  • Yuan HY, Zhang XH, Zhang XL, Wei JF, Meng L. 2014. Analysis of patents on anti-gout therapies issued in China. Expert Opin Ther Pat. 24(5):555–572.
  • Zalawadiya SK, Veeranna V, Mallikethi-Reddy S, Bavishi C, Lunagaria A, Kottam A, Afonso L. 2015. Uric acid and cardiovascular disease risk reclassification: finding NHANES III. Eur J Prev Cardiolog. 22(4):513–518.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.